Gaziano, Thomas A <br/><br/>
Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.  [electronic resource] 

 -  American heart journal  08 2019 
 - 77-87 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-6744 
<br/><br/><label>Standard No.: </label>10.1016/j.ahj.2019.04.020  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adrenergic beta-Antagonists--economics<br/>Aspirin--economics<br/>Atenolol--economics<br/>Budgets<br/>Cardiovascular Diseases--economics<br/>Cost Savings<br/>Cost-Benefit Analysis<br/>Drug Combinations<br/>Drug Costs<br/>Female<br/>Humans<br/>Hydroxymethylglutaryl-CoA Reductase Inhibitors--economics<br/>Life Expectancy<br/>Male<br/>Medication Adherence<br/>Middle Aged<br/>Nutrition Surveys<br/>Platelet Aggregation Inhibitors--economics<br/>Ramipril--economics<br/>Renin-Angiotensin System<br/>Secondary Prevention--economics<br/>Stroke--economics<br/>United States